Incretin Signaling and Metabolic Research: Understanding GLP-1, GIP and Glucagon Pathways

Metabolism Is Coordinated by Signals

Metabolism is sometimes described as if nutrients simply enter the body and are either burned for energy or stored. The actual process requires constant communication.

After a meal, the gastrointestinal tract detects nutrients and releases signaling molecules that help coordinate digestion, insulin secretion, appetite, glucose regulation and the handling of incoming energy.

Two of the most important signals are glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP. Both are classified as incretin hormones.

Their release after nutrient intake contributes to the increase in insulin secretion that occurs when glucose is consumed orally. Modern research has expanded that picture considerably. GLP-1 and GIP participate in a broader network involving the pancreas, gastrointestinal tract, nervous system, adipose tissue and other organs.

Understanding that network helps explain why incretin biology has become an active area of metabolic research.

What Is the Incretin Effect?

The incretin effect describes an important observation in glucose physiology.

Oral glucose produces a greater insulin response than an equivalent amount of glucose delivered intravenously under conditions producing similar blood glucose concentrations. The gastrointestinal tract is therefore doing more than absorbing glucose. It also signals that nutrients have arrived.

GLP-1 and GIP are major contributors to this response. They are secreted from enteroendocrine cells after nutrient exposure and can enhance glucose-dependent insulin secretion.

This system helps coordinate nutrient intake with the body's response to those nutrients. Incretin hormones are not simply appetite or weight-regulation signals. Their physiology begins with nutrient sensing and metabolic coordination.

GLP-1 Connects the Gut, Pancreas and Brain

GLP-1 is produced from the proglucagon gene and released from intestinal enteroendocrine cells in response to food intake. Its physiological actions span several systems.

GLP-1 can enhance glucose-dependent insulin secretion. It can suppress glucagon secretion when glucose is elevated, slow gastrointestinal motility and contribute to appetite and food-intake regulation. These effects help coordinate the transition from eating to processing and storing nutrients.

The glucose-dependent nature of the insulin response is particularly important. GLP-1 does not simply instruct the pancreas to release a fixed amount of insulin. Its insulinotropic effect depends partly on the prevailing glucose environment.

The effect of a biological signal depends on the context in which that signal occurs.

GIP Has Its Own Role in Nutrient Metabolism

GIP is the other major incretin hormone. Like GLP-1, it is released after nutrient intake and contributes to glucose-dependent insulin secretion.

GLP-1 and GIP, however, are not interchangeable. Their receptors are distributed differently, and their effects on several tissues and signaling systems differ.

One example involves glucagon. GLP-1 tends to suppress glucagon secretion when glucose is elevated. GIP can stimulate glucagon secretion under lower-glucose conditions. The two incretin hormones can therefore participate in maintaining glucose homeostasis through different mechanisms.

GIP biology also extends into adipose tissue and the central nervous system.

Researchers continue to investigate how GIP receptor signaling affects appetite, adipose biology, energy balance and the response to combined receptor agonism. Some aspects remain less settled than the physiology of GLP-1, particularly when native GIP signaling is compared with pharmacological receptor activation.

Glucagon Plays a Different Metabolic Role

Glucagon is not an incretin hormone. It is produced primarily by pancreatic alpha cells and plays an important role in maintaining glucose availability, particularly when blood glucose is low or energy demand changes.

One of glucagon's major actions is signaling the liver to increase glucose output. That can occur through processes including glycogen breakdown and gluconeogenesis.

At first glance, glucagon receptor activation can appear unusual in a metabolic strategy involving GLP-1 and GIP. GLP-1 participates in post-meal glucose regulation, while glucagon can increase hepatic glucose production.

The explanation lies in the broader actions of glucagon signaling. Glucagon also affects energy expenditure, lipid metabolism and other aspects of metabolic regulation. Researchers have investigated whether balancing glucagon receptor activity with incretin receptor activity can produce an integrated metabolic effect that differs from targeting one receptor alone.

Reviews of triple-agonist development describe this balance as part of the rationale for combining GLP-1, GIP and glucagon receptor activity.

One Receptor Became Two

The development of GLP-1 receptor pharmacology led researchers to investigate whether more than one metabolic receptor could be targeted by a single molecule. That work eventually produced dual-receptor agonism.

A prominent example is simultaneous activation of the GIP and GLP-1 receptors. This approach is scientifically interesting because GLP-1 and GIP have overlapping effects in some areas and distinct effects in others. Activating both receptors creates a pharmacological signal that differs from activating either receptor alone.

Clinical development of dual GIP/GLP-1 receptor agonism demonstrated that multi-receptor strategies could produce substantial metabolic effects in humans and expanded interest in additional combinations.

From Dual Agonism to Triple Agonism

Triple agonism combines activity at three receptor systems within one molecule. One combination receiving substantial research attention targets:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

Each contributes a different component to the overall pharmacology.

GLP-1 receptor activity is associated with glucose-dependent insulin secretion, appetite regulation and gastrointestinal effects.

GIP receptor activity contributes to glucose-dependent insulin secretion and has additional effects involving adipose tissue, glucagon regulation and central signaling.

Glucagon receptor activity introduces another dimension involving hepatic metabolism and energy expenditure.

The research question is whether a carefully designed balance across several receptors can produce a useful integrated metabolic response. That question has led to the development of triple-receptor agonists.

Retatrutide and Triple-Receptor Research

Retatrutide, also known by the research designation LY3437943, is an agonist of the GIP, GLP-1 and glucagon receptors. Its development has moved triple-receptor agonism from a theoretical concept into human clinical research.

A randomized phase 2 trial published in the New England Journal of Medicine in 2023 evaluated retatrutide in 338 adults with obesity, or overweight with at least one weight-related condition.

At 48 weeks, the least-squares mean change in body weight in the 12 mg group was -24.2%, compared with -2.1% in the placebo group. Gastrointestinal adverse events were the most commonly reported adverse events. They were generally mild to moderate, dose-related and occurred primarily during dose escalation.

These findings generated substantial interest, but they should be interpreted in the context of the study design and population.

A phase 2 clinical trial provides human evidence. It does not establish every proposed mechanism responsible for an observed outcome, and results from a specific trial population should not automatically be generalized beyond the population studied.

Subsequent reviews and meta-analyses have continued to evaluate available retatrutide evidence while emphasizing the need for larger and longer clinical datasets.

For readers interested specifically in laboratory research surrounding this molecule, Vial Drop Labs' GLP-3R research resource provides compound-specific research information and associated analytical documentation.

Receptor Activity Is Different From Native Hormone Physiology

A molecule that activates the GLP-1 receptor is not identical to native GLP-1. The same principle applies to GIP and glucagon receptor activation.

Pharmacological agonists can differ from endogenous hormones in receptor potency, duration of exposure, resistance to degradation, tissue exposure and balance of activity across receptors.

Multi-receptor molecules add another variable: the relative strength of activation at each receptor. Researchers can therefore design compounds with different GLP-1, GIP and glucagon receptor activity profiles.

Structural research on retatrutide has examined how the molecule interacts with all three receptors, helping characterize the molecular basis for its triple agonism. The balance among these signals is an important part of the pharmacology.

Mechanism and Outcome Are Different Questions

Multi-receptor agonism creates an important distinction when interpreting research. A compound can activate three receptors. Researchers can characterize those receptor interactions and identify downstream signaling pathways. Clinical trials can separately measure outcomes such as body weight, glucose regulation or adverse events.

Those forms of evidence answer different questions. Knowing that a molecule activates a receptor helps explain its mechanism. It does not establish the magnitude of a clinical outcome. Likewise, observing an outcome in a clinical trial does not establish that every proposed molecular mechanism caused that outcome.

Keeping mechanism and outcome separate is particularly important in emerging areas of research.

Metabolic Outcomes Extend Beyond Scale Weight

Attention surrounding incretin-based research often centers on body weight, but clinical studies also evaluate glucose regulation, HbA1c, waist circumference, blood pressure, lipids and other cardiometabolic outcomes.

This connects with a broader principle discussed in our article on metabolic health biomarkers.

Body weight is one measurement within a much larger metabolic picture. Changes in glucose regulation, insulin signaling, lipid metabolism, blood pressure and body composition can provide additional information about what is happening physiologically.

The Research Is Moving Beyond Single Pathways

Human metabolism is controlled by networks of signals.

Food intake affects gut hormones. Gut hormones influence pancreatic signaling. Pancreatic hormones affect nutrient storage and mobilization. The brain participates in appetite and energy regulation. Adipose tissue functions as an endocrine organ. The liver regulates nutrient availability. Skeletal muscle consumes and stores metabolic substrates.

These systems communicate continuously. Multi-receptor research attempts to influence several parts of that network at the same time.

Whether a particular combination produces meaningful outcomes must ultimately be established through controlled research rather than inferred from the number of receptors involved. Three targets are not automatically better than two, and two are not automatically better than one. The evidence has to demonstrate the outcome.

What the Evidence Tells Us

GLP-1 and GIP are nutrient-responsive incretin hormones that participate in glucose-dependent insulin secretion.

GLP-1 also affects glucagon secretion, gastrointestinal function, appetite and food intake. GIP has overlapping and distinct physiological effects, and researchers continue to investigate its actions in pancreatic, adipose and central nervous system signaling.

Glucagon plays an important role in maintaining energy availability and has become part of multi-receptor metabolic research.

Dual GIP/GLP-1 receptor agonism demonstrated that simultaneous receptor targeting could produce substantial metabolic effects in humans.

Retatrutide extended that research into simultaneous GIP, GLP-1 and glucagon receptor agonism, with published phase 2 clinical data showing substantial changes in body weight and other metabolic measures.

Important questions remain. Researchers continue to study the contribution of each receptor, the balance among receptor activities, longer-term outcomes, tolerability and differences among populations. Those uncertainties define areas where additional evidence is still needed.

From Hormone Signaling to the Bigger Metabolic Picture

GLP-1, GIP and glucagon illustrate how coordinated human metabolism is.

The gastrointestinal tract detects nutrients and releases signals. The pancreas responds. The liver adjusts nutrient availability. The brain influences appetite. Adipose tissue and skeletal muscle participate in energy storage and use.

Modern incretin research has increasingly moved from studying these pathways individually toward examining how several can be influenced simultaneously.

The useful question is not simply which receptor a compound activates. It is how those signals interact, what outcomes are observed in controlled research and how strong the evidence is for the conclusions being drawn.

That distinction keeps emerging metabolic research in perspective.